Philogen S.p.A. (PHIL.MI)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Duccio Neri | Co-Founder & Executive Chairman | -- | -- | -- |
| Prof. Dario Neri Ph.D. | Co-Founder, CEO , MD, CSO, President of the Scientific Advisory Board & Director | -- | -- | 1963 |
| Dr. Giovanni Neri | Co-Founder, Head of IP & Licensing and Executive Director | -- | -- | -- |
| Ms. Laura Baldi | Chief Financial Officer | -- | -- | -- |
| Dr. Alfredo Covelli M.D. | Chief Medical Officer | -- | -- | -- |
| Dr. Katia Lorizzo | Deputy CMO & Head of Clinical Operations | -- | -- | -- |
Philogen S.p.A.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 165
Description
Philogen S.p.A., a biotechnology company, develops drugs for oncology and chronic inflammatory diseases. It is developing Nidlegy, a combination of the immunocytokines L19IL2 and L19TNF developed intralesional treatment for locoregional melanoma and non-melanoma skin cancers; Fibromun, a human immunomodulatory product consisting of L19 antibody and TNF to treat soft tissue sarcoma, leiomyosarcoma, and glioma; and Darleukin (L19IL2), a human immunostimulatory product consisting of the human L19 antibody fused to the human cytokine interleukin-2 (IL2), which is in phase II clinical trial for the treatment of non-small cell lung cancer. The company is also developing Dodekin, a human immunostimulatory product that comprises vascular targeting antibody fused to interleukin-12 that is in phase I/II clinical trial to treat advanced solid tumors; Dekavil (F8IL10), an anti-inflammatory product, which is in phase II clinical trial for the treatment of chronic inflammatory disorders; Onco IX (PHC-102), a 99mTc labelled small molecule radiotracer for the non-invasive detection of carbonic anhydrase IX (CAIX) expressed on the surface of solid tumors that is in phase 1 clinical trial; and OncoFAP, a small molecule radiotracer for the non-invasive detection of various metastatic solid tumors targeting fibroblast activation protein, which is in phase 1 clinical trial. In addition, it is developing Tripokin, a fully-human immunostimulatory product consisting of tumor necrosis factor and interleukin-2 fused into one molecular entity, which is in preclinical stage. Philogen S.p.A. was founded in 1996 and is based in Siena, Italy.
Corporate Governance
Recent Events
Recent Events Information Not Available
Upcoming Events
Upcoming Events Information Not Available